Document Type

Journal Article

Authors

Hiu Yee Kwan, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Xuyan Niu, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Wenlin Dai, Department of Mathematics, Hong Kong Baptist University
Tiejun Tong, Department of Mathematics, Hong Kong Baptist UniversityFollow
Xiaojuan Chao, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Tao Su, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Chi Leung Chan, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Kim Chung Lee, Agilent Technology, Hong Kong Limited
Xiuqiong Fu, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Hua Yi, Department of Pathology, Guangzhou University of Chinese Medicine
Hua Yu, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Ting Li, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Anfernee Kai Wing Tse, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Wang Fun Fong, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University
Si-Yuan Pan, Department of Pharmacology, Beijing University of Chinese Medicine
Aiping Lu, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Zhi-Ling Yu, Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist UniversityFollow

Department/Unit

School of Chinese Medicine

Title

Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers

Language

English

Abstract

© 2015, Nature Publishing Group. All rights reserved. Schisandrin B (SchB) is one of the most abundant bioactive dibenzocyclooctadiene derivatives found in the fruit of Schisandra chinensis. Here, we investigated the potential therapeutic effects of SchB on non-alcoholic fatty-liver disease (NAFLD). In lipidomic study, ingenuity pathway analysis highlighted palmitate biosynthesis metabolic pathway in the liver samples of SchB-treated high-fat-diet-fed mice. Further experiments showed that the SchB treatment reduced expression and activity of fatty acid synthase, expressions of hepatic mature sterol regulatory element binding protein-1 and tumor necrosis factor-α, and hepatic level of palmitic acid which is known to promote progression of steatosis to steatohepatitis. Furthermore, the treatment also reduced hepatic fibrosis, activated nuclear factor-erythroid-2-related factor-2 which is known to attenuate the progression of NASH-related fibrosis. Interestingly, in fasting mice, a single high-dose SchB induced transient lipolysis and increased the expressions of adipose triglyceride lipase and phospho-hormone sensitive lipase. The treatment also increased plasma cholesterol levels and 3-hydroxy-3-methylglutaryl-CoA reductase activity, reduced the hepatic low-density-lipoprotein receptor expression in these mice. Our data not only suggest SchB is a potential therapeutic agent for NAFLD, but also provided important information for a safe consumption of SchB because SchB overdosed under fasting condition will have adverse effects on lipid metabolism.

Publication Date

2015

Source Publication Title

Scientific Reports

Volume

5

Start Page

9114

Publisher

Nature Publishing Group

DOI

10.1038/srep09114

Link to Publisher's Edition

http://dx.doi.org/10.1038/srep09114

ISSN (print)

20452322

ISSN (electronic)

20452322

This document is currently not available here.

Share

COinS